Cargando…

Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.

Gemcitabine (dFdC), a deoxycitidine nucleoside analogue, inhibits DNA synthesis and repair of radiation-induced chromosome breaks in vitro, radiosensitizes various human and mouse cells in vitro and shows clinical activity in several tumours. Limited data are however available on the effect of dFdC...

Descripción completa

Detalles Bibliográficos
Autores principales: Grégoire, V., Beauduin, M., Rosier, J. F., De Coster, B., Bruniaux, M., Octave-Prignot, M., Scalliet, P.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228152/
https://www.ncbi.nlm.nih.gov/pubmed/9374377
_version_ 1782149845286387712
author Grégoire, V.
Beauduin, M.
Rosier, J. F.
De Coster, B.
Bruniaux, M.
Octave-Prignot, M.
Scalliet, P.
author_facet Grégoire, V.
Beauduin, M.
Rosier, J. F.
De Coster, B.
Bruniaux, M.
Octave-Prignot, M.
Scalliet, P.
author_sort Grégoire, V.
collection PubMed
description Gemcitabine (dFdC), a deoxycitidine nucleoside analogue, inhibits DNA synthesis and repair of radiation-induced chromosome breaks in vitro, radiosensitizes various human and mouse cells in vitro and shows clinical activity in several tumours. Limited data are however available on the effect of dFdC on normal tissue radiotolerance and on factors associated with dFdC's radiosensitization in vivo. The purpose of this study was to determine the effect of dFdC on mouse jejunum radiosensitization and to investigate the kinetics of DNA synthesis inhibition and cell cycle redistribution in the jejunal crypts as surrogates of radiosensitization in vivo. For assessment of jejunum tolerance, the mice were irradiated on the whole body with 60Co gamma rays (3.5-18 Gy single dose) with or without prior administration of dFdC (150 mg kg-1). Jejunum tolerance was evaluated by the number of regenerated crypts per circumference at 86 h after irradiation. For pharmacodynamic studies, dFdC (150 or 600 mg kg-1) was given i.p. and jejunum was harvested at various times (0-48 h), preceded by a pulse BrdUrd labelling. Labelled cells were detected by immunohistochemistry on paraffin-embedded sections. DNA synthesis was inhibited within 3 h after dFdC administration. After an early wave of apoptosis (3-6 h), DNA synthesis recovered by 6 h, and crypt cells became synchronized. At 48 h, the labelling index returned almost to background level. At a level of 40 regenerated crypts, radiosensitization was observed for a 3 h time interval (dose modification factor of 1.3) and was associated with DNA synthesis inhibition, whereas a slight radioprotection was observed for a 48-h time interval (dose modification factor of 0.9) when DNA synthesis has reinitiated. In conclusion, dFdC altered the radioresponse of the mouse jejunum in a schedule-dependent fashion. Our data tend to support the hypothesis that DNA synthesis inhibition and cell cycle redistribution are surrogates for radiosensitization. More data points are however required before a definite conclusion can be drawn. IMAGES:
format Text
id pubmed-2228152
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22281522009-09-10 Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells. Grégoire, V. Beauduin, M. Rosier, J. F. De Coster, B. Bruniaux, M. Octave-Prignot, M. Scalliet, P. Br J Cancer Research Article Gemcitabine (dFdC), a deoxycitidine nucleoside analogue, inhibits DNA synthesis and repair of radiation-induced chromosome breaks in vitro, radiosensitizes various human and mouse cells in vitro and shows clinical activity in several tumours. Limited data are however available on the effect of dFdC on normal tissue radiotolerance and on factors associated with dFdC's radiosensitization in vivo. The purpose of this study was to determine the effect of dFdC on mouse jejunum radiosensitization and to investigate the kinetics of DNA synthesis inhibition and cell cycle redistribution in the jejunal crypts as surrogates of radiosensitization in vivo. For assessment of jejunum tolerance, the mice were irradiated on the whole body with 60Co gamma rays (3.5-18 Gy single dose) with or without prior administration of dFdC (150 mg kg-1). Jejunum tolerance was evaluated by the number of regenerated crypts per circumference at 86 h after irradiation. For pharmacodynamic studies, dFdC (150 or 600 mg kg-1) was given i.p. and jejunum was harvested at various times (0-48 h), preceded by a pulse BrdUrd labelling. Labelled cells were detected by immunohistochemistry on paraffin-embedded sections. DNA synthesis was inhibited within 3 h after dFdC administration. After an early wave of apoptosis (3-6 h), DNA synthesis recovered by 6 h, and crypt cells became synchronized. At 48 h, the labelling index returned almost to background level. At a level of 40 regenerated crypts, radiosensitization was observed for a 3 h time interval (dose modification factor of 1.3) and was associated with DNA synthesis inhibition, whereas a slight radioprotection was observed for a 48-h time interval (dose modification factor of 0.9) when DNA synthesis has reinitiated. In conclusion, dFdC altered the radioresponse of the mouse jejunum in a schedule-dependent fashion. Our data tend to support the hypothesis that DNA synthesis inhibition and cell cycle redistribution are surrogates for radiosensitization. More data points are however required before a definite conclusion can be drawn. IMAGES: Nature Publishing Group 1997 /pmc/articles/PMC2228152/ /pubmed/9374377 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Grégoire, V.
Beauduin, M.
Rosier, J. F.
De Coster, B.
Bruniaux, M.
Octave-Prignot, M.
Scalliet, P.
Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.
title Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.
title_full Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.
title_fullStr Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.
title_full_unstemmed Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.
title_short Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.
title_sort kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of dna synthesis inhibition and cell cycle redistribution in crypt cells.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228152/
https://www.ncbi.nlm.nih.gov/pubmed/9374377
work_keys_str_mv AT gragoirev kineticsofmousejejunumradiosensitizationby22difluorodeoxycytidinegemcitabineanditsrelationshipwithpharmacodynamicsofdnasynthesisinhibitionandcellcycleredistributionincryptcells
AT beauduinm kineticsofmousejejunumradiosensitizationby22difluorodeoxycytidinegemcitabineanditsrelationshipwithpharmacodynamicsofdnasynthesisinhibitionandcellcycleredistributionincryptcells
AT rosierjf kineticsofmousejejunumradiosensitizationby22difluorodeoxycytidinegemcitabineanditsrelationshipwithpharmacodynamicsofdnasynthesisinhibitionandcellcycleredistributionincryptcells
AT decosterb kineticsofmousejejunumradiosensitizationby22difluorodeoxycytidinegemcitabineanditsrelationshipwithpharmacodynamicsofdnasynthesisinhibitionandcellcycleredistributionincryptcells
AT bruniauxm kineticsofmousejejunumradiosensitizationby22difluorodeoxycytidinegemcitabineanditsrelationshipwithpharmacodynamicsofdnasynthesisinhibitionandcellcycleredistributionincryptcells
AT octaveprignotm kineticsofmousejejunumradiosensitizationby22difluorodeoxycytidinegemcitabineanditsrelationshipwithpharmacodynamicsofdnasynthesisinhibitionandcellcycleredistributionincryptcells
AT scallietp kineticsofmousejejunumradiosensitizationby22difluorodeoxycytidinegemcitabineanditsrelationshipwithpharmacodynamicsofdnasynthesisinhibitionandcellcycleredistributionincryptcells